Approximately 61% of the prostate cancer cases in this cohort lacked PTEN expression, as assessed by the IHC score, with a trend of increased frequency of PTEN loss in WHO-ISUP GG5 cases (Table 2). This evidence concerns the gene PTEN and prostate cancer.